US a key market, have strong presence in it: Ankur Vaid, Concord Biotech
So we expect to do better than what we have done historically, which was a CAGR growth of 18%. And this as economies of scale would kick in once a new site starts ramping up, we see our margin profiling being better than what it has been historically, which has been in the range of around 40%.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
